A contingent of scientists is wary about the coronavirus vaccine frontrunners, which could receive approval from the Food and Drug Administration within the next year. They worry the leading candidates focus too much on a single protein, the coronavirus's distinctive spike, and believe the vaccines should optimize a different part of the immune response.
↧